Research and Markets (http://www.researchandmarkets.com/research/4whrfr/abilify_major)
has announced the addition of the "Abilify
(Major Depressive Disorder) - Forecast and Market Analysis to 2023"
report to their offering.
Abilify (aripiprazole) is an atypical antipsychotic indicated for use as
an adjunctive treatment for MDD in patients who have not adequately
responded to antidepressant therapy in the US. Abilify is available in
the 5EU, Japan, and Australia, but is not indicated for the treatment of
MDD, and as such, it is being used as an off-label treatment, as
validated by our primary research survey in January 2014.
Overview of Major depressive disorder, including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
Detailed information on Abilify including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Abilify for the top eight countries from 2013 to
Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Abilify (Aripiprazole)
For more information visit http://www.researchandmarkets.com/research/4whrfr/abilify_major
Copyright Business Wire 2014